kynurenic acid has been researched along with Depressive Disorder in 17 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
Depressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Abnormalities of the kynurenine (KYN) pathway may be implicated in the pathophysiology of depression." | 8.98 | Kynurenine pathway in depression: A systematic review and meta-analysis. ( Graff-Guerrero, A; Iwata, Y; Kubo, K; Mimura, M; Miyazaki, T; Moriguchi, S; Nakajima, S; Noda, Y; Ogyu, K; Omura, Y; Plitman, E; Tarumi, R; Tsugawa, S; Uchida, H; Wada, M, 2018) |
| "In both cohorts, inflammation as measured by higher levels of CRP, sVCAM1 and sICAM1 was associated with kynurenine/tryptophan ratio and thus enhanced tryptophan breakdown (beta: 0." | 7.88 | Psychosocial stress and inflammation driving tryptophan breakdown in children and adolescents: A cross-sectional analysis of two cohorts. ( Carvalho, LA; Clarke, G; Díaz, LE; Gómez-Martínez, S; Marcos, A; Michels, N; Olavarria-Ramirez, L; Widhalm, K, 2018) |
| "We evaluated 101 patients with chronic hepatitis C treated with PEG-IFN-α2a, and 40 controls, so as to determine the activation of indolamine 2,3-dioxygenase (IDO) and tryptophan (TRP) and their metabolites' concentrations/levels: kynurenine (KYN), kynurenic acid (KYNA) and anthranilic acid (AA)." | 7.88 | Alterations in the metabolism of tryptophan in patients with chronic hepatitis C six months after pegylated interferon-α 2a treatment. ( Inglot, M; Laskus, T; Malyszczak, K; Pawlak, D; Pawlowski, T; Radkowski, M; Zalewska, M, 2018) |
| "Ketamine has rapid antidepressant effects on treatment-resistant depression, but the biological mechanism underpinning this effect is less clear." | 7.88 | Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. ( Chen, L; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2018) |
| "The aim of the present study was to compare blood serum kynurenic acid (KYNA) concentrations measured before ECT and after 1, 6 and 12 electroconvulsive treatment (ECT) sessions in patients with diagnoses of recurrent depressive disorder (RDD), depression in bipolar disorder (DBD) and schizoaffective disorder (SAD)." | 7.85 | Blood serum concentrations of kynurenic acid in patients diagnosed with recurrent depressive disorder, depression in bipolar disorder, and schizoaffective disorder treated with electroconvulsive therapy. ( Olajossy, B; Olajossy, M; Potembska, E; Urbańska, E; Wnuk, S, 2017) |
| "Abnormalities of the kynurenine (KYN) pathway may be implicated in the pathophysiology of depression." | 4.98 | Kynurenine pathway in depression: A systematic review and meta-analysis. ( Graff-Guerrero, A; Iwata, Y; Kubo, K; Mimura, M; Miyazaki, T; Moriguchi, S; Nakajima, S; Noda, Y; Ogyu, K; Omura, Y; Plitman, E; Tarumi, R; Tsugawa, S; Uchida, H; Wada, M, 2018) |
| "In both cohorts, inflammation as measured by higher levels of CRP, sVCAM1 and sICAM1 was associated with kynurenine/tryptophan ratio and thus enhanced tryptophan breakdown (beta: 0." | 3.88 | Psychosocial stress and inflammation driving tryptophan breakdown in children and adolescents: A cross-sectional analysis of two cohorts. ( Carvalho, LA; Clarke, G; Díaz, LE; Gómez-Martínez, S; Marcos, A; Michels, N; Olavarria-Ramirez, L; Widhalm, K, 2018) |
| "We evaluated 101 patients with chronic hepatitis C treated with PEG-IFN-α2a, and 40 controls, so as to determine the activation of indolamine 2,3-dioxygenase (IDO) and tryptophan (TRP) and their metabolites' concentrations/levels: kynurenine (KYN), kynurenic acid (KYNA) and anthranilic acid (AA)." | 3.88 | Alterations in the metabolism of tryptophan in patients with chronic hepatitis C six months after pegylated interferon-α 2a treatment. ( Inglot, M; Laskus, T; Malyszczak, K; Pawlak, D; Pawlowski, T; Radkowski, M; Zalewska, M, 2018) |
| "Ketamine has rapid antidepressant effects on treatment-resistant depression, but the biological mechanism underpinning this effect is less clear." | 3.88 | Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. ( Chen, L; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2018) |
| "The aim of the present study was to compare blood serum kynurenic acid (KYNA) concentrations measured before ECT and after 1, 6 and 12 electroconvulsive treatment (ECT) sessions in patients with diagnoses of recurrent depressive disorder (RDD), depression in bipolar disorder (DBD) and schizoaffective disorder (SAD)." | 3.85 | Blood serum concentrations of kynurenic acid in patients diagnosed with recurrent depressive disorder, depression in bipolar disorder, and schizoaffective disorder treated with electroconvulsive therapy. ( Olajossy, B; Olajossy, M; Potembska, E; Urbańska, E; Wnuk, S, 2017) |
| "Xanthurenic acid is a metabolite of L-tryptophanicotinic acid ribonucleotide biosynthesis." | 2.65 | The clinical significance of disordered renal excretion of xanthurenic acid in depressive patients. ( Hoes, MJ; Sijben, N, 1981) |
| "Quinolinic acid was increased and kynurenic acid decreased over time in suicidal patients versus healthy controls." | 1.42 | A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. ( Bay-Richter, C; Brundin, L; Erhardt, S; Guillemin, GJ; Lim, CK; Linderholm, KR; Samuelsson, M; Träskman-Bendz, L, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.76) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 13 (76.47) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Olajossy, M | 1 |
| Olajossy, B | 1 |
| Wnuk, S | 1 |
| Potembska, E | 1 |
| Urbańska, E | 1 |
| Ogyu, K | 1 |
| Kubo, K | 1 |
| Noda, Y | 1 |
| Iwata, Y | 1 |
| Tsugawa, S | 1 |
| Omura, Y | 1 |
| Wada, M | 1 |
| Tarumi, R | 1 |
| Plitman, E | 1 |
| Moriguchi, S | 1 |
| Miyazaki, T | 1 |
| Uchida, H | 1 |
| Graff-Guerrero, A | 1 |
| Mimura, M | 1 |
| Nakajima, S | 1 |
| Michels, N | 1 |
| Clarke, G | 1 |
| Olavarria-Ramirez, L | 1 |
| Gómez-Martínez, S | 1 |
| Díaz, LE | 1 |
| Marcos, A | 1 |
| Widhalm, K | 1 |
| Carvalho, LA | 1 |
| Pawlowski, T | 1 |
| Malyszczak, K | 1 |
| Inglot, M | 1 |
| Zalewska, M | 1 |
| Radkowski, M | 1 |
| Laskus, T | 1 |
| Pawlak, D | 1 |
| Zhou, Y | 1 |
| Zheng, W | 1 |
| Liu, W | 1 |
| Wang, C | 1 |
| Zhan, Y | 1 |
| Li, H | 1 |
| Chen, L | 1 |
| Li, M | 1 |
| Ning, Y | 1 |
| Harkin, A | 2 |
| McLoughlin, DM | 1 |
| Baranyi, A | 1 |
| Meinitzer, A | 1 |
| Stepan, A | 1 |
| Putz-Bankuti, C | 1 |
| Breitenecker, RJ | 1 |
| Stauber, R | 1 |
| Kapfhammer, HP | 1 |
| Rothenhäusler, HB | 1 |
| Bay-Richter, C | 1 |
| Linderholm, KR | 1 |
| Lim, CK | 1 |
| Samuelsson, M | 1 |
| Träskman-Bendz, L | 1 |
| Guillemin, GJ | 1 |
| Erhardt, S | 2 |
| Brundin, L | 1 |
| Guloksuz, S | 1 |
| Arts, B | 1 |
| Walter, S | 1 |
| Drukker, M | 1 |
| Rodriguez, L | 1 |
| Myint, AM | 1 |
| Schwarz, MJ | 1 |
| Ponds, R | 1 |
| van Os, J | 1 |
| Kenis, G | 1 |
| Rutten, BP | 1 |
| Li, CF | 1 |
| Chen, XM | 1 |
| Chen, SM | 1 |
| Mu, RH | 1 |
| Liu, BB | 1 |
| Luo, L | 1 |
| Liu, XL | 1 |
| Geng, D | 1 |
| Liu, Q | 1 |
| Yi, LT | 1 |
| Liu, XC | 1 |
| Goiny, M | 1 |
| Engberg, G | 1 |
| Mathé, AA | 1 |
| Maes, M | 2 |
| Galecki, P | 1 |
| Verkerk, R | 1 |
| Rief, W | 1 |
| Tiganov, AS | 1 |
| Kopeĭko, GI | 1 |
| Brusov, OS | 1 |
| Kliushnik, TP | 1 |
| Mihaylova, I | 1 |
| Ruyter, MD | 1 |
| Kubera, M | 1 |
| Bosmans, E | 1 |
| Hoes, MJ | 1 |
| Sijben, N | 1 |
| Bermond, P | 1 |
| Nally, R | 1 |
| Kelly, JP | 1 |
| Leonard, BE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation[NCT05866575] | 136 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for kynurenic acid and Depressive Disorder
| Article | Year |
|---|---|
Kynurenine pathway in depression: A systematic review and meta-analysis.
Topics: Brain; Depression; Depressive Disorder; Humans; Kynurenic Acid; Kynurenine; Quinolinic Acid | 2018 |
[New findings in the study of the pathogenesis and treatment of endogenous depression].
Topics: Biomarkers; Cytokines; Depressive Disorder; Humans; Kynurenic Acid; Tryptophan | 2012 |
1 trial available for kynurenic acid and Depressive Disorder
| Article | Year |
|---|---|
The clinical significance of disordered renal excretion of xanthurenic acid in depressive patients.
Topics: 17-Hydroxycorticosteroids; Adult; Anxiety Disorders; Depressive Disorder; Female; Humans; Kynurenic | 1981 |
14 other studies available for kynurenic acid and Depressive Disorder
| Article | Year |
|---|---|
Blood serum concentrations of kynurenic acid in patients diagnosed with recurrent depressive disorder, depression in bipolar disorder, and schizoaffective disorder treated with electroconvulsive therapy.
Topics: Adult; Case-Control Studies; Depression; Depressive Disorder; Electroconvulsive Therapy; Female; Hum | 2017 |
Psychosocial stress and inflammation driving tryptophan breakdown in children and adolescents: A cross-sectional analysis of two cohorts.
Topics: Adolescent; C-Reactive Protein; Child; Cohort Studies; Cross-Sectional Studies; Cytokines; Depressio | 2018 |
Alterations in the metabolism of tryptophan in patients with chronic hepatitis C six months after pegylated interferon-α 2a treatment.
Topics: Adult; Antiviral Agents; Depression; Depressive Disorder; Female; Hepatitis C; Hepatitis C, Chronic; | 2018 |
Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression.
Topics: Administration, Intravenous; Adult; Antidepressive Agents; Bipolar Disorder; China; Chromatography, | 2018 |
Ketamine and depression: A special kase for kynurenic acid?
Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder; Humans; Ketamine; Kynurenic Acid; K | 2019 |
A biopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis C infection.
Topics: Adult; Analysis of Variance; Depressive Disorder; Female; Hepatitis C, Chronic; Humans; Indoleamine- | 2013 |
A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality.
Topics: Adult; Cytokines; Depressive Disorder; Female; Humans; Inflammation; Kynurenic Acid; Kynurenine; Mal | 2015 |
The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway.
Topics: Adult; Aged; Depressive Disorder; Electroconvulsive Therapy; Female; Humans; Kynurenic Acid; Kynuren | 2015 |
Activation of hippocampal BDNF signaling is involved in the antidepressant-like effect of the NMDA receptor antagonist 7-chlorokynurenic acid.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder; Disease Mode | 2016 |
Decreased levels of kynurenic acid in prefrontal cortex in a genetic animal model of depression.
Topics: Animals; Cerebellum; Chromatography, Liquid; Corpus Striatum; Depressive Disorder; Disease Models, A | 2017 |
Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity.
Topics: Adult; Age Factors; Analysis of Variance; Biomarkers; Depressive Disorder; Diagnostic and Statistica | 2011 |
The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
Topics: Adult; Anti-Inflammatory Agents; Cytokines; Depressive Disorder; Female; Gene Expression Regulation; | 2007 |
Therapy of side effects of oral contraceptive agents with vitamin B6.
Topics: Contraceptives, Oral; Contraceptives, Oral, Hormonal; Depressive Disorder; Dose-Response Relationshi | 1982 |
Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and beta1-adrenergic receptors in an animal model of depression.
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Animals; Cerebral Cortex; Depressive Diso | 2000 |